17β-trenbolone, an anabolic-androgenic steroid as well as an environmental hormone, contributes to neurodegeneration

Toxicol Appl Pharmacol. 2015 Jan 1;282(1):68-76. doi: 10.1016/j.taap.2014.11.007. Epub 2014 Nov 25.

Abstract

Both genetic and environmental factors contribute to neurodegenerative disorders. In a large number of neurodegenerative diseases (for example, Alzheimer's disease (AD)), patients do not carry the mutant genes. Other risk factors, for example the environmental factors, should be evaluated. 17β-trenbolone is a kind of environmental hormone as well as an anabolic-androgenic steroid. 17β-trenbolone is used as a growth promoter for livestock in the USA. Also, a large portion of recreational exercisers inject 17β-trenbolone in large doses and for very long time to increase muscle and strength. 17β-trenbolone is stable in the environment after being excreted. In the present study, 17β-trenbolone was administered to adult and pregnant rats and the primary hippocampal neurons. 17β-trenbolone's distribution and its effects on serum hormone levels and Aβ42 accumulation in vivo and its effects on AD related parameters in vitro were assessed. 17β-trenbolone accumulated in adult rat brain, especially in the hippocampus, and in the fetus brain. It altered Aβ42 accumulation. 17β-trenbolone induced apoptosis of primary hippocampal neurons in vitro and resisted neuroprotective function of testosterone. Presenilin-1 protein expression was down-regulated while β-amyloid peptide 42 (Aβ42) production and caspase-3 activities were increased. Both androgen and estrogen receptors mediated the processes. 17β-trenbolone played critical roles in neurodegeneration. Exercisers who inject large doses of trenbolone and common people who are exposed to 17β-trenbolone by various ways are all influenced chronically and continually. Identification of such environmental risk factors will help us take early prevention measure to slow down the onset of neurodegenerative disorders.

Keywords: 17β-trenbolone; Alzheimer's disease; Aβ42; Neurodegeneration; Presenilin-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Peptides / metabolism
  • Anabolic Agents / metabolism
  • Anabolic Agents / toxicity*
  • Androgens / metabolism
  • Androgens / toxicity*
  • Animals
  • Animals, Newborn
  • Apoptosis / drug effects
  • Caspase 3 / metabolism
  • Cell Survival / drug effects
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Endocrine Disruptors / metabolism
  • Endocrine Disruptors / toxicity*
  • Estradiol / blood
  • Female
  • Hippocampus / drug effects*
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Male
  • Nerve Degeneration*
  • Neurons / drug effects*
  • Neurons / metabolism
  • Neurons / pathology
  • Peptide Fragments / metabolism
  • Presenilin-1 / metabolism
  • Progesterone / blood
  • Rats, Wistar
  • Receptors, Androgen / drug effects
  • Receptors, Androgen / metabolism
  • Receptors, Estrogen / drug effects
  • Receptors, Estrogen / metabolism
  • Risk Assessment
  • Testosterone / blood
  • Time Factors
  • Tissue Distribution
  • Trenbolone Acetate / metabolism
  • Trenbolone Acetate / toxicity*

Substances

  • Amyloid beta-Peptides
  • Anabolic Agents
  • Androgens
  • Endocrine Disruptors
  • Peptide Fragments
  • Presenilin-1
  • Receptors, Androgen
  • Receptors, Estrogen
  • amyloid beta-protein (1-42)
  • Testosterone
  • Progesterone
  • Estradiol
  • Casp3 protein, rat
  • Caspase 3
  • Trenbolone Acetate